Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16456544 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kobayashi M, et al. (2006) MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration. EMBO J 25, 713-26 16456544
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S3-p - cofilin 1 (human) ▲
Orthologous residues
cofilin 1 (human): S3‑p, cofilin 1 (mouse): S3‑p, cofilin 1 (rat): S3‑p, cofilin 1 (pig): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial), MSS31 (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE LIMK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE LIMK1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
VEGF, SB203580 inhibit treatment-induced increase

S310-p - LIMK1 (human) ▲
Orthologous residues
LIMK1 (human): S310‑p, LIMK1 (mouse): S310‑p, LIMK1 (rat): S310‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)

S323-p - LIMK1 (human) ▲
Orthologous residues
LIMK1 (human): S323‑p, LIMK1 (mouse): S323‑p, LIMK1 (rat): S323‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site
 Relevant cell lines - cell types - tissues:  HUVEC (endothelial), MSS31 (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF VEGFR-2 (human) increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced
 Effect of modification (process):  cell motility, altered
 Comments:  important for VEGF-induced stress fiber formation

T334-p - MAPKAPK2 (human) ▲
Orthologous residues
MAPKAPK2 (human): T334‑p, MAPKAPK2 (mouse): T320‑p, MAPKAPK2 (rat): T320‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  MSS31 (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.